Evaluation of Efficacy of Present Fixed Dose Combinations for Daily Antitubercular Treatment Under RNTCP
DOI:
https://doi.org/10.37506/qke06k17Keywords:
Efficacy, FDC, RNTCP.Abstract
Introduction:
Tuberculosis still accounts for millions of cases of active disease and deaths worldwide. The disease mainly affects the developing countries. Modern Anti-tubercular treatment can cure virtually all patients provided correct combination treatment is taken in amount and duration. Treatment of TB has been shifted towards daily regimen with administration of daily fixed dose combination of first- line ATD as per appropriate weight bands.
Objectives:
- To study efficacy of RNTCP recommended Anti TB FDCs in different weight ranges of weight Bands.
Materials and Methods: A Prospective cohort study was conducted involving a total of 830 patients presenting to Department of Respiratory Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, Sion, Mumbai with diagnosed tuberculosis and Registered for CAT I and CAT II ATT. Duration of study was 21 months. Follow up was done at the end of intensive phase (2 months) [at the end of maximum 3 months in extrapulmonary TB] and at the end of continuation phase (6 months for Cat I and 8 months for Cat II patients). Outcome of ATT was studied in different weight bands as per RNTCP. (Cure, Failure and treatment completed). Data was analyzed using SPSS version 22.0.
Result:
Among treatment categories, most patients (78.6%) were registered under Category I (new patients) as compared to retreatment cases (Category II and Category I Retreatment). Among PTB patients cure rate was 78.2%, while among EPTB patients treatment completion rate was 85.2%. Compliance of patients was better with FDCs due to reduced pill load, single dose administration, can be conveniently given to patients of all weights as per their weight bands.
Conclusion: Among PTB patients cure rate was 78.2%, while among EPTB patients treatment completion rate was 85.2%.
References
Wu JT, Chiu CT, Wei YF, Lai YF. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Clinics (Sao Paulo). 2015 Jun;70(6):429-34.
National TB Elimination Programme. Guidelines for programmatic management of TB preventive treatment in India 2021. Available from: https://tbcindia.gov.in/WriteReadData/l892s/Guidelines%20for%20Programmatic%20Management%20of%20Tuberculosis%20Preventive%20Treatment%20in%20India.pdf
Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis. 1998;2((1)):10–15.
RajavardhanaThamineni, Ramalingam Peraman, Jayakumar Chenniah, Geethavani Meka, Ashok Kumar Munagala, Vijayakumar Thangavel Mahalingam, RajanandhMuhasaparur Ganesan. A European Journal of Tropical Medicine & International Health. 2022;(27(11):1011-1023.
Moulding T, Dutt AK, Reichman LB. Fixed-dose combinations of anti-tuberculous medications to prevent drug resistance. Ann Intern Med. 1995;122((12)):951–4.
Cross A, Gupta N, Liu B, Nair V, Kumar A, Kuttan R, et al. 99DOTS: a low-cost approach to monitoring and improving medication adherence. ACM international conference proceeding series; Association for computing, Machinery, NY; 2019. https://doi.org/10.1145/3287098.3287102.
Iftikha S, Sarwar MR. Potential Disadvantages Associated with Treatment of Active Tuberculosis Using Fixed-Dose Combination: A Review of Literature. J Basic Clin Pharma 2017;8: S131-136
Sama JN, Chida N, Polan RM, Nuzzo J, Page K, Shah M. High proportion of extrapulmonary tuberculosis in a low prevalence setting: a retrospective cohort study. Public Health. 2016 Sep;138:101-7.
Teferi MY, Didana LD, Hailu T, Woldesenbet SG, Bekele S, Mihret A. Tuberculosis treatment outcome and associated factors among tuberculosis patients at Wolayta Sodo Teaching and Referral Hospital, Southern Ethiopia: a retrospective study. J Public Health Res. 2021;10(3):2046.
Ahmed S, Shukla I, Fatima N, Varshney SK, Shameem M, Tayyaba U. Profile of drug-resistant-conferring mutations among new and previously treated pulmonary tuberculosis cases from Aligarh region of Northern India. Int J Mycobacteriol. 2018;7(4):315-327.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Vaibhav Aglawe Vaibhav, NilkanthT. Awad Nilkanth, Jairaj P Nair, Bhadke B B, Sucheta S Bhalerao, Gayatri S Nair, Priya N Deshpande
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en